Abstract: EGFRTKI plays an important role in the treatment of nonsmallcell lung cancer. However, some researchers find that there are still some patients with primary or acquired resistance to EGFRTKI. The present known mechanisms of acquired drug resistance finally lead to the reactivation EGFR downstream signaling pathways. Liver X receptor agonist has inhibition function to several critical steps of EGFR downstream signaling pathways PI3KAktNFκB, which makes it possible to overcome the drug resistance.

Key words: Receptor, epidermal growth factor, Carcinoma, nonsmallcell lung, Drug resistance, Liver X receptor